Skip to main content

Table 1 The change of drug price index for bid-winning and non-winning products pre- and post-“4 + 7” policy

From: Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

 

LP

PP

FP

Pre-

Post-

GR (%)

Pre-

Post-

GR (%)

Pre-

Post-

GR (%)

Bid-winning products

 Mean

1.00

0.44

−56.37

1.00

0.42

−57.45

0.50

0.09

−81.35

 SD

0.01

0.03

0.01

0.03

0.01

0.01

 Min

0.99

0.42

0.99

0.41

0.49

0.09

 Max

1.00

0.53

1.00

0.51

0.50

0.13

Non-winning products

 Mean

0.99

0.96

−2.32

0.99

0.89

−9.91

0.49

0.43

−11.96

 SD

0.01

0.02

0.01

0.04

0.01

0.03

 Min

0.97

0.94

0.97

0.85

0.47

0.41

 Max

1.00

1.00

1.00

1.00

0.50

0.50

  1. LP: Laspeyres Price Index; PP: Paasche Price Index; FP: Fisher Price Index; Pre-: pre-“4 + 7” policy, i.e. July 2018 to February 2019; Post-: post-“4 + 7” policy, i.e. March 2019 to December 2019
  2. GR growth rate, SD standard deviation